# A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT06341335** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 506 (estimated)

## Conditions studied

- Gastric and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** cadonilimab
- **DRUG:** pulocimab
- **DRUG:** paclitaxel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06341335
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2026-11
- **Final completion:** 2027-07
- **Target enrollment:** 506 (ESTIMATED)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06341335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06341335, "A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06341335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*